In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Ziopharm Oncology Inc (NASDAQ:ZIOP) reported that Cvi Investments, Inc. has picked up 9,708,738 of common stock as of 2017-05-22.
The acquisition brings the aggregate amount owned by Cvi Investments, Inc. Limited Partnership to a total of 9,708,738 representing less than 6.8% stake in the company.
For those not familiar with the company, ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease. It has developed an adenoviral vector, Ad-RTS-IL-12, which is administered intra-tumorally under the control of the RheoSwitch Therapeutic System (RTS) expression platform. Its initial clinical stage product candidate, which is being developed using the immuno-oncology platform is Ad-RTS-IL-12 + veledimex. Ad-RTS-IL-12 + veledimex uses its gene delivery system to produce interleukin-12. As of December 31, 2016, it had completed two Phase II studies evaluating Ad-RTS-IL-12 + veledimex, for the treatment of metastatic melanoma and metastatic breast cancer.
A glance at Ziopharm Oncology Inc (NASDAQ:ZIOP)’s key stats reveals a current market capitalization of 944.63 Million based on 142.09 Million shares outstanding and a price at last close of $7.00 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2015-02-09, Kirk picked up 1,440,000 at a purchase price of $8.75. This brings their total holding to 17,830,305 as of the date of the filing.
On the sell side, the most recent transaction saw Belbel unload 153,333 shares at a sale price of $12.84. This brings their total holding to 59,201.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Ziopharm Oncology Inc (NASDAQ:ZIOP) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.